We identified relatively few, mostly small studies with short-term follow-up and design limitations. The effects of SSRIs compared with placebo are uncertain with too few studies to draw clear conclusions. There may be a small improvement in sleep quality with short-term use of low-dose doxepin and trazodone compared with placebo. The tolerability and safety of antidepressants for insomnia is uncertain due to limited reporting of adverse events. There was no evidence for amitriptyline (despite common use in clinical practice) or for long-term antidepressant use for insomnia. High-quality trials of antidepressants for insomnia are needed.

It is uncertain whether sleep preferentially consolidates emotional over neutral material. Some studies suggest that sleep enhances emotional memory (i.e., that there are large differences in strength of memory for valenced material compared to neutral material after a sleep-filled interval, but that this difference is smaller after a wake-filled interval). Others find no such effect. We attempted to resolve this uncertainty by conducting a meta-analysis that compared valenced to neutral material after both sleep- and wake-filled delays. Standard search strategies identified 31 studies (containing 36 separate datasets) that met our inclusion criteria. Using random effects modeling, we conducted separate analyses for datasets comparing (a) negative vs. neutral material, (b) positive vs. neutral material, or (c) combined negative and positive vs. neutral material. We then specified several subgroup analyses to investigate potential moderators of the relationship between sleep and emotional memory consolidation. Results showed no overall effect for preferential sleep-dependent consolidation of emotional over neutral material. However, moderation analyses provided evidence for stronger effects when (a) studies used free recall rather than recognition outcome measures, or (b) delayed recall or recognition outcomes were controlled for initial learning. Those analyses also suggested that other methodological features (e.g., whether participants experience a full night of sleep and a regular daytime waking control condition rather than a nap and a night-time sleep deprivation control condition) and sample characteristics (e.g. all-male or not, young adult or not) should be carefully addressed in future research in this field. These findings suggest that sleep does enhance emotional memory, but that in the laboratory the effect is only observed under particular methodological conditions. The conditions we identify as being critical to consider are consistent with general theories guiding scientific understanding of memory consolidation during sleep.

These preliminary findings, although requiring replication in larger samples, suggest an important association between hyperarousal symptoms and sleep quality in PTSD, and may help explain why some PTSD-diagnosed individuals experience markedly disrupted sleep whereas others do not. (PsycINFO Database Record

Symptoms of sleep disturbance, particularly nightmares and insomnia, are a central feature of post‐traumatic stress disorder (PTSD). Emerging evidence suggests that specific treatment of PTSD‐related sleep disturbance improves other symptoms of the disorder, which in turn suggests that such disturbance may be fundamental to development and maintenance of the disorder. This mini‐review focuses on pharmacological treatment of sleep disturbance in adult PTSD (specifically, studies testing the efficacy of antidepressants, adrenergic inhibiting agents, antipsychotics and benzodiazepine and non‐benzodiazepine hypnotics). We conclude that only prazosin, an adrenergic inhibiting agent, has had its efficacy established by multiple randomised controlled trials. There is also high‐level evidence supporting use of eszopiclone, as well as risperidone and olanzapine as adjunct therapy. Antidepressants such as sertraline, venlafaxine and mirtazapine, benzodiazepines such as alprazolam and clonazepam and non‐benzodiazepine hypnotics such as zolpidem appear ineffective in treating PTSD‐related sleep disturbance. Most studies that report reduced frequency of nightmares and insomnia also report decreases in overall symptom severity. Such findings suggest that (i) sleep disruption is central to PTSD; (ii) treating sleep disruption may be an effective way to address other symptoms of the disorder and (iii) PTSD symptoms tend to cluster together in predictable ways. Copyright © 2016 John Wiley & Sons, Ltd.